Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.zyduscadila.com | |
Market Cap | 101,151.67 Cr. | |
Enterprise Value(EV) | 100,394.57 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 29.55 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 34.01 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.54 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 187.28 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 5.37 | Calculated using Price: 1,005.25 |
Dividend Yield | 0.60 | Period Ending 2023-03 |
No. of Shares Subscribed | 100.62 Cr. | 1,006,233,990 Shares |
FaceValue | 1 | |
About Zydus Lifesciences Ltd. | ||
The company is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain of innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), active pharmaceutical ingredients (APIs), animal healthcare products and consumer wellness products. Innovation is the backbone of the company as it ensures business sustainability through continuous availability of new products for various businesses. |
1 Day |
|
+0.77% |
1 Week |
|
+3.70% |
1 Month |
|
+6.84% |
3 Month |
|
+46.28% |
6 Month |
|
+66.46% |
1 Year |
|
+109.04% |
2 Year |
|
+180.48% |
5 Year |
|
+205.26% |
10 Year |
|
+409.25% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 30.85 | 38.62 | 23.47 | 22.5 | 19.36 | 11.32 | 18.88 | 15.51 | 11.6 | |
Return on Capital Employed (%) | 23.21 | 28.6 | 16.52 | 18.55 | 15.89 | 10.02 | 14.38 | 15.3 | 13.64 | |
Return on Assets (%) | 13.93 | 20.14 | 12.2 | 11.23 | 9.34 | 5.18 | 9.66 | 9.4 | 7.82 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 4,252 | 5,699 | 6,960 | 8,745 | 10,386 | 10,376 | 12,992 | 17,000 | 17,516 | 18,733 | |
Non Curr. Liab. | 1,342 | 736 | 1,903 | 2,122 | 3,491 | 2,854 | 19 | -194 | -725 | -1,116 | |
Curr. Liab. | 3,285 | 3,461 | 5,306 | 6,072 | 7,343 | 8,269 | 7,861 | 7,827 | 5,527 | 4,363 | |
Minority Int. | 169 | 136 | 156 | 191 | 1,293 | 1,335 | 1,937 | 2,054 | 2,173 | 2,208 | |
Equity & Liab. | 9,047 | 10,032 | 14,325 | 17,141 | 22,513 | 22,834 | 22,810 | 26,700 | 24,494 | 24,188 | |
Non Curr. Assets | 4,820 | 5,752 | 8,303 | 8,911 | 14,015 | 14,118 | 14,094 | 14,438 | 14,478 | 14,253 | |
Curr. Assets | 4,227 | 4,280 | 6,022 | 8,201 | 8,498 | 8,715 | 8,716 | 12,095 | 10,008 | 9,935 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 9,047 | 10,032 | 14,325 | 17,141 | 22,513 | 22,834 | 22,810 | 26,700 | 24,494 | 24,188 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 8,651 | 9,427 | 9,377 | 11,905 | 13,166 | 14,253 | 14,404 | 15,110 | 17,237 | 19,024 | |
Other Income | 57 | 117 | 147 | 133 | 209 | 117 | 75 | 391 | 475 | 268 | |
Total Income | 8,709 | 9,543 | 9,524 | 12,038 | 13,374 | 14,370 | 14,479 | 15,501 | 17,712 | 19,293 | |
Total Expenditure | -6,897 | -7,097 | -7,472 | -9,058 | -10,187 | -11,473 | -11,018 | -11,935 | -13,666 | -14,118 | |
PBIDT | 1,811 | 2,446 | 2,051 | 2,980 | 3,187 | 2,897 | 3,460 | 3,565 | 4,047 | 5,175 | |
Interest | -68 | -53 | -63 | -111 | -196 | -342 | -186 | -127 | -130 | -74 | |
Depreciation | -287 | -292 | -373 | -539 | -599 | -697 | -670 | -713 | -723 | -737 | |
Taxation | -259 | -177 | -129 | -564 | -530 | -320 | -194 | -512 | -588 | -794 | |
Exceptional Items | -10 | -3 | 0 | -10 | -364 | -205 | 113 | -604 | -616 | ||
PAT | 1,186 | 1,921 | 1,486 | 1,766 | 1,852 | 1,176 | 2,206 | 2,326 | 2,002 | 2,954 | |
Minority Interest | -38 | -30 | -29 | -35 | -50 | -28 | -51 | -131 | -132 | -111 | |
Share Associate | 43 | 34 | 63 | 47 | 29 | 47 | 46 | 95 | 113 | ||
Other Related Items | 2 | ||||||||||
Consolidated Net Profit | 1,151 | 1,934 | 1,488 | 1,776 | 1,849 | 1,177 | 2,134 | 4,487 | 1,960 | 2,974 | |
Adjusted EPS | 11 | 19 | 15 | 17 | 18 | 11 | 21 | 44 | 19 | 29 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 903 | 994 | 1,894 | 1,312 | 919 | 1,282 | 2,932 | 3,294 | 2,105 | 2,689 | |
Cash Fr. Inv. | -438 | -465 | -864 | -2,872 | -974 | -4,239 | -1,012 | -725 | -1,000 | 1,171 | |
Cash Fr. Finan. | -529 | -351 | -935 | 2,316 | 52 | 1,885 | -1,528 | -2,548 | -868 | -4,400 | |
Net Change | -64 | 178 | 95 | 756 | -3 | -1,072 | 391 | 22 | 236 | -540 | |
Cash & Cash Eqvt | 613 | 790 | 837 | 1,593 | 1,590 | 779 | 1,178 | 1,087 | 1,107 | 573 |
Wed, 27 Mar 2024
Updates Zydus Lifesciences Limited has informed the Exchange regarding 'Inspection held at SEZ Onco Injectable site'. |
Tue, 26 Mar 2024
Updates Zydus Lifesciences Limited has informed the Exchange that Proposed sale of 6,23,000 equity shares of the face value of ₹ 1 each ( Equity Shares ) of Zydus Lifesciences Limited ( the Company ) held by Zydus Family Trust, being member of the promoter group of the Company (the Seller ) in the open market for achieving minimum public shareholding ( MPS ) |
Tue, 26 Mar 2024
Trading Window Zydus Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
Thu, 28 Mar 2024 |
Close Within 52 Week High Zone |
Close Above Last Month High |
High Increase in 1 Month |
High Increase in 3 Months |
High Increase in 6 Months |